ロード中...
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews
BACKGROUND: Relenza represents the first neuraminidase inhibitor (NI), a class of drugs that also includes the drug Tamiflu. Although heralded as breakthrough treatments in influenza, NI efficacy has remained highly controversial. A key unsettled question is why the United States Food and Drug Admin...
保存先:
| 出版年: | Health Res Policy Syst |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5680823/ https://ncbi.nlm.nih.gov/pubmed/29121959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12961-017-0259-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|